(Stroke. 1997;28:799-804.)
© 1997 American Heart Association, Inc.
Articles |
From the Cerebrovascular Research Laboratory, Section of Cerebrovascular Surgery, The Cleveland Clinic Foundation (Ohio).
Correspondence to Douglas Chyatte, MD, Section of Cerebrovascular Surgery, S80, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail chyattd{at}cesmtp.ccf.org
| Abstract |
|---|
|
|
|---|
Methods Cultured skin fibroblasts and serum samples were studied in patients with angiographic evidence of aneurysm (n=31) and control subjects (n=14). Transcription of the type III collagen gene was assessed with the use of Northern blots prepared from RNA harvested from confluent cultured fibroblasts. Translation of type III collagen was assessed by Western blot analysis of proteins produced by cultured skin fibroblasts. Collagen metabolism was assessed by radioimmunoassay for type I (PICP) and type III (PIIINP) procollagen peptides in conditioned tissue culture media and serum. We assessed collagen degradation in serum and conditioned tissue culture media by evaluating gelatinase activity using quantitative zymography.
Results Type III collagen synthesis was the same in aneurysm and control patients. Neither the molecular weight nor the relative amount of type III collagen mRNA differed between aneurysm and control patient fibroblasts. Western blot analysis revealed no difference in the relative amount or molecular weight of procollagen III synthesized by aneurysm and control cells. Aneurysm patients had a threefold increase in native serum gelatinase activity compared with control subjects (P=.004). This increase occurred along with serum evidence of increased collagen metabolism. Serum levels of PICP (P=.03) and PIIINP (P=.02) were decreased in aneurysm patients. Elevated serum gelatinase activity and altered collagen metabolism could not be explained by enhanced secretion of gelatinase by cultured fibroblasts or altered net collagen synthesis by fibroblasts. High serum gelatinase activity was more common in men than in women (P=.04).
Conclusions These findings are consistent with the hypothesis that accelerated enzymatic degradation of collagens and other structural proteins compromises the mechanical integrity of the cerebral vessel wall and leads to conditions that favor aneurysm formation.
Key Words: cerebral aneurysm collagen gelatinases subarachnoid hemorrhage
| Introduction |
|---|
|
|
|---|
Relatively little is known about the biology of cerebral aneurysms, and no hypothesis is accepted uniformly that explains the formation and subsequent rupture of intracranial aneurysms. Understanding the conditions that lead to intracranial aneurysm formation and rupture may allow new prophylactic strategies and new aneurysm treatments to be developed.
Research indicates that there is likely one or more biochemical abnormalities unique to aneurysm patients.1 Approximately half of all aneurysm patients have an observable morphological derangement of the cerebral arteries that is related to deficiencies of structural proteins that maintain the mechanical integrity of the cerebral artery wall.16 17 18 19 20 21 22 23 24 Initially, it was believed that only a type III collagen deficiency was commonly associated with cerebral aneurysms.1 16 19 21 24 However, others have since found that mutations in the gene for type III collagen are not a common cause of aneurysms25 and that total collagen, rather than only type III, is decreased in the cerebral arteries of some patients.21 Decreases in arterial collagen may result from impaired collagen synthesis or enhanced degradation. In this study we tested the hypothesis that enhanced collagen degradation, not impaired synthesis, is associated with the occurrence of cerebral aneurysms.
| Subjects and Methods |
|---|
|
|
|---|
Experimental Design
To evaluate type III collagen synthesis, we evaluated
transcription of the type III collagen gene (COL3A1) using Northern
blots. Translation of both type I and type III collagen was assessed in
both serum and conditioned tissue culture media by radioimmunoassay
(RIA) for procollagen peptides I and III. Mature type III collagen was
evaluated by Western blot analysis of trypsin-soluble proteins
produced by cultured fibroblasts. Collagen degradation was measured by
studying gelatinase activity in both serum and conditioned tissue
culture media with the use of quantitative zymography. These
biochemical data were then examined for any correspondences with
clinical data.
Clinical Data and Sample Collection
Clinical data were collected by reviewing medical records.
Data were collected on patient age, sex, diagnosis, presence or absence
of aneurysm rupture (subarachnoid hemorrhage),
aneurysm location, aneurysm size, number of
aneurysms, neurological grade at admission, and family
history.
Blood samples were collected immediately before surgery by venipuncture, and the serum was separated after clotting by centifugation. The samples were aliquoted and immediately frozen at -70°C for later analysis. Skin samples were immediately placed in culture (D-MEM-F12; Gibco) and transported to the laboratory where the fibroblast cultures were prepared.
Fibroblast Cultures
Fresh skin specimens were trimmed of excess fat and subcutaneous
tissue and minced into 2- to 3-mm fragments. These were allowed to dry;
then culture medium (D-MEM-F12; Gibco) was added, and the specimens
were incubated at 37°C in a 95% O2/5%
CO2 atmosphere. Confluent cultures were prepared by serial
passage of cells. Conditioned medium was prepared with serum-free
medium (Aim-V; Gibco) and a 72-hour conditioning period. Aliquots of
conditioned media were stored at -70°C for later assay. The cell
count (determined with a hemocytometer) and amount of deoxyribonucleic
acid DNA were determined (Quigen DNA kit) and then used to normalize
conditioned media protein and enzyme levels on a per cell basis.
Trypsin digestion was used to solubilize proteins, including type III
collagen that had been synthesized by confluent fibroblasts and
deposited in the extracellular matrix. Trypsinized supernatants were
aliquoted and stored at -70°C for later assay.
Northern Blots
To determine the transcription level of the type III
collagen gene, Northern blots were done. Total RNA was extracted from
confluent cultured skin fibroblasts (Trizol Reagent; Gibco). Each RNA
sample then was dissolved in diethylpyrocarbonate-treated distilled
water and denatured by heating at 65°C for 10 minutes in a standard
denaturing solution. The RNA was fractioned by agarose electrophoresis
and transferred to a nitrocellulose membrane. The membranes were
hybridized with a cDNA probe (HF934; American Type Culture Collection)
for type III collagen mRNA by means of a nonradioactive labeling
technique (Photogene Nucleic Acid Detection System; Gibco). A
commercially available cDNA probe for ß-actin (Oncor) was used as a
standard for normalization.
Western Blots
Trypsinized samples were separated by
polyacrylamide gel electrophoresis, blotted, and then probed
with the use of a commercially available polyclonal antibody to type
III collagen (polyclonal rabbit anti-human procollagen III antibody;
Biodesign) and a peroxidase-labeled secondary antibody (Amersham).
Determination of Conditioned Media Procollagen
Peptide Levels
To determine whether the collagen deficiency observed in some
aneurysm patients results from a global depression in the
synthesis rate of all collagens, the synthesis rates of type I and type
III procollagen were estimated by measuring the procollagen peptide
levels for type I and type III collagen in serum-free media conditioned
with cultured skin fibroblasts. During the conversion of procollagen to
collagen, specific proteases cleave propeptides from both the
carboxyterminal and aminoterminal ends of mature procollagen. Both the
carboxyterminal and aminoterminal propeptides are produced in a 1:1
stoichiometry for each procollagen molecule released. Levels of these
propeptides reflect the net synthesis of collagen. Propeptide levels,
however, may also be decreased by accelerated proteolytic activity.
The carboxyterminal propeptide for type I collagen (PICP) and the aminoterminal propeptide for type III collagen (PIIINP) were measured by RIA with a commercially available kit (Incstar). Propeptide levels for both collagens were measured in conditioned serum-free tissue culture media in aneurysm patients and compared with control subjects. Before the conditioning period, serum was present in the culture media. Cell counts in all conditioning flasks were similar. Normalizing peptide levels on a per cell basis did not alter results.
Determination of Serum Procollagen Peptide Levels
To determine whether the collagen deficiency observed in some
patients results from a global depression in the synthesis rate of all
collagens, the in vitro synthesis rates of type I and type III
procollagen were estimated by measuring the procollagen peptide level
for type I and type III collagen in serum.
PICP and PIIINP levels were measured in serum samples with an RIA kit (Incstar). As for procollagen produced by cultured cells, levels of these propeptides reflect net collagen synthesis unless peptide levels are decreased by accelerated proteolytic activity.
Assessment of Gelatinase Activity
Zymography was used to assess gelatinase activity in the serum
samples and conditioned serum-free tissue culture media. Aliquots of
conditioned media (10 µg protein) or serum (10 µL of 1:200
dilution) were loaded onto substrate gels. Gelatinase substrate gel
electrophoresis26 27 28 was performed with the use of precast
gels (10% polyacrylamide containing 0.1% gelatin; Novex).
Samples were prepared for analysis by dilution into a loading
buffer consisting of 0.4 mol/L Tris, pH 6.8, 5% sodium dodecyl
sulfate, 20% glycerol, and 0.03% bromophenol blue. After
electrophoresis at 125 V, the gels were incubated in renaturing
solution (2.5% Triton X-100) for 30 minutes at room temperature and
then for 72 hours at 37°C in a developing buffer containing 50 mol/L
Tris, pH 7.5, 200 mmol/L NaCl, 4 mmol/L CaCl, and 0.02%
Brij-35. The gels were then stained with 0.5% Coomassie blue G-250 in
30% methanol/10% acetic acid and then destained in 30% methanol/10%
acetic acid. Finally, the gels were incubated for 15 minutes in 30%
methanol and 5% glycerol and stored between sheets of cellophane.
Gelatinase activity appears as unstained bands in the gel. The
digestion was quantified with the use of a gel scanner equipped with an
interface to a Macintosh computer. Gels were analyzed with the
aid of NIH-Image software, version 1.41. Each gel was scanned three
times, and the mean value of the integrated density for a particular
unstained band was used for analysis. Gelatinase activity was
quantified by normalizing sample activity to a standard composed of
pooled serum or conditioned media.
Statistical Analysis
All analyses were run in triplicate; the mean of the
three assays was determined and used for statistical analysis.
The primary comparison made was between all aneurysm patients
and control patients; a secondary comparison involved differences
between patients with high or low gelatinase activity and control
subjects. For biochemical measurements, the mean±SD was determined.
Student's t test was used to test for differences in PICP,
PIIINP, and gelatinase activity between patients and control subjects.
For clinical data, differences between aneurysm and control
patients were tested with the t test or Yates' correction
to the
2 test, as appropriate. The post hoc
comparison between high gelatinase activity, low gelatinase activity,
and control groups was done in a similar fashion. Bonferroni's
correction, to correct for the effect of multiple comparisons, was used
for these analyses. Differences were considered statistically
significant at P<.05.
| Results |
|---|
|
|
|---|
|
Northern Blot Results
Northern blots were performed on 21 aneurysm and 7 control
patients. Neither the molecular weight (5.4 kb) nor relative amount of
mRNA (band densities of type III collagen mRNA) differed between
aneurysm patients and control subjects. Fig 1
shows a typical Northern blot for collagen type III. Type III collagen
gene expression was normal in all aneurysm patients.
|
Western Blot Results
Western blots were performed in 21 aneurysm and 7 control
patients. No difference in the relative amount or molecular weight of
procollagen III synthesized by aneurysm and control cells was
detected. Fig 2
shows a typical Western blot for type
III collagen.
|
Serum and Conditioned Media Gelatinase and Procollagen
Peptide
Zymograms and RIAs for PICP and PIIINP were performed on samples
from 31 aneurysm and 14 control patients (Table 2
). Aneurysm patients had a threefold increase
in native serum gelatinase activity compared with control subjects
(P=.004). This increase was accompanied by lower serum
procollagen peptide levels, suggesting that enzymatic degradation of
collagen was increased. Serum levels of both PICP (P=.03)
and PIIINP (P=.02) were significantly lower in
aneurysm patients. No significant differences were observed in
media gelatinase activities (P=.23), media PICP levels
(P=.08), or media PIIINP levels (P=.19) between
aneurysm and control patients (Table 2
). The enhanced serum
gelatinase activity did not appear to be due to a gelatinase unique to
aneurysm patients, as the predominant band of gelatinase
activity was at 72 kD in both aneurysm and control patients
(Fig 3
).
|
|
Not all aneurysm patients had equally increased serum
gelatinase activity levels (Table 3
). Post hoc
analysis was performed to compare aneurysm patients
with obviously increased gelatinase activity to aneurysm
patients not showing increased gelatinase activity. Aneurysm
patients were considered "high activity" if their serum
gelatinase activity was at least two times greater than mean control
values and "low activity" if their serum gelatinase level was
less than two times mean control values. Of the aneurysm
patients, 16 had high serum gelatinase activity and differed
significantly compared with aneurysm patients with low levels
and with control subjects (P<.0001). Collagen
metabolism was clearly altered in this high-activity
subgroup. Serum levels of PICP (P=.01) and PIIINP
(P=.02) were decreased compared with those of control
subjects. Media gelatinase (P=.07), media PICP
(P=.21), and media PIIINP (P=.26) did not differ
between the high-activity group and control subjects.
|
Of aneurysm patients, 15 showed low serum gelatinase activity. No significant differences were found in serum gelatinase activity (P=.93), serum PICP (P=.16), media gelatinase (P=.56), media PICP (P=.66), or media PIIINP (P=.20) compared with control subjects. Serum PIIINP was significantly reduced in low-activity patients (P=.003) compared with control subjects, suggesting a derangement in collagen metabolism despite normal gelatinase activity. There were nine men in the high-activity subgroup but only three in the low-activity group (P=.04). Other clinical features of the high-activity group were similar to those of the low-activity group. No difference was found in the mean age (P=.60), incidence of subarachnoid hemorrhage (P=.85), aneurysm location (P=.71), or aneurysm size (P=.71). Data regarding family history were missing in 22 patients (71%) and therefore were not analyzed.
| Discussion |
|---|
|
|
|---|
Currently, it is not understood why aneurysms form or rupture. Two general hypotheses regarding rupture have been investigated. In one hypothesis, exaggerated hemodynamic forces or hemodynamic imbalances are believed to lead to aneurysm formation and rupture.2 29 30 31 32 33 34 35 36 37 38 39 Exaggerated hemodynamic forces do appear to contribute to aneurysm formation under certain conditions in both humans and animals,1 40 41 42 but hemodynamic forces alone do not appear to be sufficient to cause cerebral aneurysms. For example, in animals, induced hypertension (increased hemodynamic stress) and carotid ligation (hemodynamic imbalance) must be coupled with lathyrism, which compromises the structural integrity of collagen in the vascular connective tissue, to reliably produce cerebral aneurysms.40 41 42 In humans, although hypertension is a risk factor for cerebral aneurysms, they rarely develop in hypertensive individuals.6 These observations indicate that conditions other than hypertension alone must be present to produce cerebral aneurysms.
In the second hypothesis, aneurysm formation is linked to biochemical defects that undermine the mechanical integrity of the vessel wall. As discussed below, considerable evidence exists supporting this hypothesis for a significant proportion of patients.
Cerebral artery morphology provides some insight into cerebral aneurysm formation. The extracellular scaffolding has three main components. Reticular fibers are complexes of the extracellular scaffolding composed of collagen fibrils 20 to 40 µm in diameter in close association with other structural matrix molecules43 44 and form a supporting framework around vascular smooth muscle cells. Aneurysm patients have a 35% reduction in histologically apparent reticular fibers in both cerebral and somatic arteries, pointing to a generalized abnormality in the arterial bed of some patients with ruptured aneurysms.16 19 22 Reticular fibers are irregularly distributed in aneurysm patients and often appear shorter and coarser than normal. Collagen fibers, in contrast, are cord-shaped structures 1 to 20 µm in diameter. Collagen fibers appear similar in both aneurysm and control patients.16 19 22 Elastin is a relatively minor component of cerebral arteries, limited almost exclusively to the internal elastic lamina. No differences have been found between elastin morphology in aneurysm patients and control subjects.16 19 22
The initial biochemical investigations of cerebral
aneurysms focused on type III collagen, a major structural
component of the arterial wall, and examined whether
cerebral aneurysm patients have a specific deficiency of type
III collagen. Pope et al24 and Neil-Dwyer et
al19 compared tissue levels and synthetic rates of type
III collagen in aneurysm patients with brain tumor patients who
served as control subjects. Type III collagen levels and synthetic
rates were normalized with respect to type I collagen levels. To
determine type III levels in tissue, pepsin digests of skin and
superficial temporal arteries were prepared, and type III and type I
collagen were separated by gel electrophoresis under reducing and
nonreducing conditions. Both groups concluded that approximately half
of all aneurysm patients had a type III collagen deficiency
relative to type I collagen. However, these differences may be merely
the result of artifacts arising from unequal gel loading. Neil-Dwyer et
al19 also measured collagen synthesis rates by feeding
cultured skin fibroblasts with radiolabeled proline or lysine and
comparing the relative amounts of type I and type III collagen as
determined by carboxymethyl cellulose chromatography.
Approximately half of the aneurysm patients "produced
significantly less" type III collagen than control subjects (7.5%
versus 10.5%). However, the
-1 (III) and
-2 peaks overlapped
considerably such that the 3% difference may be an artifact of peak
size estimation.
Others evaluated this hypothesis by comparing collagen content and the biomechanical properties of the middle cerebral and brachial arteries of aneurysm patients and control patients.21 Collagen content was estimated by measuring the hydroxyproline content of the arteries. The relative ratio of hydroxyproline in type III to type I collagen was calculated from sodium dodecyl sulfatepolyacrylamide gel electrophoresis band sizes of the cyanogen bromide peptides of collagen. Approximately half of the aneurysm patients had a decrease in the estimated type III collagen content relative to type I in both cerebral and brachial arteries. Deficient middle cerebral arteries had normal tensile strengths but increased extensibility at stresses corresponding to physiologically relevant blood pressures. They concluded that some aneurysm patients have type III collagen deficiency and that this deficiency alters the biomechanical properties of the arterial wall. The arterial samples that were identified as type III collagen deficient, however, had a decrease in total hydroxyproline. These patients, therefore, may have had a decrease in total collagen content rather than an isolated deficiency of only type III collagen.
Kuivaniemi et al25 sequenced the coding sequence of the
type III collagen gene (Col3A1) in 58 aneurysm patients and
found powerful evidence that mutations in the gene for type III
procollagen are not a common cause of intracranial aneurysms.
After cDNAs were prepared and sequenced, polymorphisms and
mutations were confirmed with the use of genomic DNA. When mutations
were identified, type III collagen from cultured fibroblasts was
analyzed, and stability to pepsin digestion was measured. Of
the 58 patients, 42 had polymorphic sites. Expression of both
alleles in these 42 individuals appeared to be equal. Mutations in
the type III collagen sequence were found in two individuals; both
mutations resulted in an amino acid substitution (Pro 435
Thr and Pro
468
Leu). Neither mutation affected the relative amount of type III
procollagen synthesized as determined with gel electrophoresis or
stability to pepsin digestion.
Despite the evidence provided by Kuivaniemi et al,25 the
possibility remains that decreased type III collagen is associated with
cerebral aneurysms. Majamaa et al45 studied
radiolabeled type I and type III collagen synthesized by cultured skin
fibroblasts from 11 aneurysm patients. Although amounts of type
I and type III collagen did not differ between patients and control
subjects, a decrease in thermal stability to trypsin and
-chymotrypsin digestion was observed in two of the 11
aneurysm patients (39°C versus 41°C).
Relatively little work has been done to evaluate the possibility that
accelerated proteolytic activity may lead to the global decrease in
arterial collagen observed in some aneurysm
patients. Recently, Baker et al46 compared serum
elastase and
1-antitrypsin levels in patients with
ruptured or unruptured aneurysms with control patients. They
found that the serum elastase level was significantly elevated in
patients with either ruptured or unruptured aneurysms.
1-Antitrypsin levels were normal in all aneurysm
patients. Enzyme activity was not measured, and the possibility that
elastase may degrade substrates other than elastin was not
studied.
The present study extends the understanding of type III collagen synthesis in aneurysm patients by examining the levels of type III collagen transcription and translation. No difference in type III collagen transcription or translation was found in fibroblasts prepared from aneurysm and control patients. A primary derangement of type III collagen synthesis, therefore, does not explain the decrease in arterial structural proteins found in many aneurysm patients and is not a common cause of intracranial aneurysms. Alternatively, this decrease may be the result of accelerated collagen degradation. Such degradation would compromise the mechanical integrity of the cerebral vessel wall and lead to conditions that favor aneurysm formation. Serum gelatinase activity was increased in half the aneurysm patients studied and was accompanied by lower serum procollagen peptide levels, reflecting increased enzymatic degradation.
Conclusions
The present study links increased serum gelatinase
activity to the occurrence of cerebral aneurysms. Cerebral
aneurysms therefore may occur as the result of a complex
remodeling process involving the degradation matrix proteins and not as
the result of passive dilation alone.
| Acknowledgments |
|---|
Received January 14, 1997; accepted January 14, 1997.
| References |
|---|
|
|
|---|
-1-antitrypsin levels in patients
with ruptured and unruptured cerebral aneurysms.
Neurosurgery. 1995;37:56-62.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
H. Ohkuma, S. Suzuki, S. Fujita, and W. Nakamura Role of a Decreased Expression of the Local Renin-Angiotensin System in the Etiology of Cerebral Aneurysms Circulation, August 19, 2003; 108(7): 785 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hashimoto, G. Wen, M. T. Lawton, N. J. Boudreau, A. W. Bollen, G.-Y. Yang, N. M. Barbaro, R. T. Higashida, C. F. Dowd, V. V. Halbach, et al. Abnormal Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Brain Arteriovenous Malformations * Growth and Bleeding in BAVM: Another Role for MMPs Stroke, April 1, 2003; 34(4): 925 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Krex, A. Ziegler, H. K. Schackert, and G. Schackert Lack of Association Between Endoglin Intron 7 Insertion Polymorphism and Intracranial Aneurysms in a White Population: Evidence of Racial/Ethnic Differences Stroke, November 1, 2001; 32(11): 2689 - 2694. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Guillon, C. Tzourio, V. Biousse, V. Adrai, M. G. Bousser, and P. J. Touboul Arterial wall properties in carotid artery dissection: An ultrasound study Neurology, September 12, 2000; 55(5): 663 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Peters, A. Kassam, P. L. St. Jean, H. Yonas, and R. E. Ferrell Functional Polymorphism in the Matrix Metalloproteinase-9 Promoter as a Potential Risk Factor for Intracranial Aneurysm Stroke, December 1, 1999; 30(12): 2612 - 2616. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. P. van den Berg, G. Pals, F. Arwert, R. C. M. Hennekam, K. W. Albrecht, A. Westerveld, and M. Limburg Type III Collagen Deficiency in Saccular Intracranial Aneurysms : Defect in Gene Regulation? Stroke, August 1, 1999; 30(8): 1628 - 1631. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Todor, I. Lewis, G. Bruno, and D. Chyatte Identification of a Serum Gelatinase Associated With the Occurrence of Cerebral Aneurysms as Pro-Matrix Metalloproteinase-2 Stroke, August 1, 1998; 29(8): 1580 - 1583. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |